Literature DB >> 9303416

In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.

M Manduru1, L B Mihm, R L White, L V Friedrich, P A Flume, J A Bosso.   

Abstract

The concentration/MIC (C/MIC) ratio maximizing the bactericidal activity of ceftazidime against 10 Pseudomonas aeruginosa isolates from cystic fibrosis patients was identified. Bactericidal activity was assessed by determining the percent difference in the area under the killing curve at each C/MIC ratio for all of the isolates from that of their growth control. The percent effect at each C/MIC ratio was fitted to a sigmoidal Emax model with maximum bactericidal activity defined as the C/MIC ratio that produced an effect that was 90% of the Emax. Our results suggest that at least some isolates may require higher C/MIC ratios than previously reported for maximal activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9303416      PMCID: PMC164067          DOI: 10.1128/AAC.41.9.2053

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  [Bactericidal dosie-activity relationships with E. coli, K. pneumoniae and Staph. aureus (author's transl)].

Authors:  P M Shah; W Stille
Journal:  Dtsch Med Wochenschr       Date:  1976-02-27       Impact factor: 0.628

2.  Protection of Pseudomonas aeruginosa against ciprofloxacin and beta-lactams by homologous alginate.

Authors:  N A Hodges; C A Gordon
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 3.  Is continuous infusion of beta-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations.

Authors:  J W Mouton; A A Vinks
Journal:  J Antimicrob Chemother       Date:  1996-07       Impact factor: 5.790

4.  Reduced susceptibility of a mucoid strain of Pseudomonas aeruginosa to lysis by ticarcillin and piperacillin.

Authors:  N Bolister; M Basker; N Hodges; C Marriott
Journal:  J Antimicrob Chemother       Date:  1989-10       Impact factor: 5.790

5.  Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.

Authors:  J W Mouton; J G den Hollander
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

6.  Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.

Authors:  D P Nicolau; C H Nightingale; M A Banevicius; Q Fu; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

7.  Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia.

Authors:  S Daenen; Z Erjavec; D R Uges; H G De Vries-Hospers; P De Jonge; M R Halie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

8.  Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.

Authors:  A S Benko; D M Cappelletty; J A Kruse; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home.

Authors:  A A Vinks; D J Touw; H G Heijerman; M Danhof; G P de Leede; W Bakker
Journal:  Ther Drug Monit       Date:  1994-08       Impact factor: 3.681

10.  Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.

Authors:  D M Cappelletty; S L Kang; S M Palmer; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  21 in total

1.  Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.

Authors:  B J Angus; M D Smith; Y Suputtamongkol; H Mattie; A L Walsh; V Wuthiekanun; W Chaowagul; N J White
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

Review 2.  Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models.

Authors:  Sofie Dhaese; Aaron Heffernan; David Liu; Mohd Hafiz Abdul-Aziz; Veronique Stove; Vincent H Tam; Jeffrey Lipman; Jason A Roberts; Jan J De Waele
Journal:  Clin Pharmacokinet       Date:  2020-10       Impact factor: 6.447

Review 3.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

4.  Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.

Authors:  Vanthida Huang; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 5.  Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.

Authors:  Charlotte Roy; Manon Launay; Sophie Magréault; Isabelle Sermet-Gaudelus; Vincent Jullien
Journal:  Clin Pharmacokinet       Date:  2021-01-24       Impact factor: 6.447

6.  Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Amy N Schilling; Shadi Neshat; Keith Poole; David A Melnick; Elizabeth A Coyle
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

7.  Comparative bactericidal activity of ceftazidime against isolates of Pseudomonas aeruginosa as assessed in an in vitro pharmacodynamic model versus the traditional time-kill method.

Authors:  M Manduru; L B Mihm; R L White; L V Friedrich; P A Flume; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

8.  Short versus long infusion of meropenem in very-low-birth-weight neonates.

Authors:  Helgi Padari; Tuuli Metsvaht; Lenne-Triin Kõrgvee; Eva Germovsek; Mari-Liis Ilmoja; Karin Kipper; Koit Herodes; Joseph F Standing; Kersti Oselin; Irja Lutsar
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

9.  Severe Keratitis Caused by Pseudomonas aeruginosa Successfully Treated with Ceftazidime Associated with Acetazolamide.

Authors:  Benoit Hue; Marc Doat; Gilles Renard; Marie-Laure Brandely; François Chast
Journal:  J Ophthalmol       Date:  2009-04-26       Impact factor: 1.909

Review 10.  Continuous infusion of beta-lactam antibiotics.

Authors:  A P MacGowan; K E Bowker
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.